Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | UNG | P13051 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6248331 | 0.86 | ALDH1A1 (0.63) | KMT2AMAPTSMN1; SMN2NPC1GAA | |
| SCHEMBL28991764 | 0.85 | ALDH1A1 (0.63) | KMT2AMAPTSMN1; SMN2NPC1GAA | |
| SCHEMBL7577334 | 0.82 | KMT2A (0.58) | KMT2AMAPTSMN1; SMN2NPC1GAA | |
| SCHEMBL8613974 | 0.81 | KMT2A (0.56) | KMT2AMAPTSMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL4459121 | 0.80 | ESR1 (0.60) | KMT2AMAPTSMN1; SMN2GAAPOLB | |
| SCHEMBL11201050 | 0.77 | NPC1 (0.57) | KMT2AMAPTSMN1; SMN2NPC1GAA | |
| SCHEMBL21418171 | 0.77 | ESR1 (0.57) | KMT2AMAPTSMN1; SMN2NPC1GAA | |
| SCHEMBL8577513 | 0.77 | SRC (0.58) | KMT2AMAPTSMN1; SMN2NPC1GAA | |
| SCHEMBL8579838 | 0.77 | SRC (0.58) | KMT2AMAPTSMN1; SMN2NPC1GAA | |
| SCHEMBL197094 | 0.77 | KMT2A (0.63) | KMT2AMAPTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
| EP-1937272-A2 | BENZODIAZEPINES AS HCV INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007026024-A2 | BENZODIAZEPINES AS HCV INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | GABRA5, GABRA4, GABRA3 | KMT2A 1440/4885MAPT 1578/4885SMN1; SMN2 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.